IL126185A - Compositions comprising an hiv protease inhibitor, a water soluble vitamin e compound and a hydrophilic non-aqueous solvent - Google Patents

Compositions comprising an hiv protease inhibitor, a water soluble vitamin e compound and a hydrophilic non-aqueous solvent

Info

Publication number
IL126185A
IL126185A IL12618597A IL12618597A IL126185A IL 126185 A IL126185 A IL 126185A IL 12618597 A IL12618597 A IL 12618597A IL 12618597 A IL12618597 A IL 12618597A IL 126185 A IL126185 A IL 126185A
Authority
IL
Israel
Prior art keywords
compositions
compound
water soluble
aqueous solvent
protease inhibitor
Prior art date
Application number
IL12618597A
Other languages
English (en)
Other versions
IL126185A0 (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL126185A0 publication Critical patent/IL126185A0/xx
Publication of IL126185A publication Critical patent/IL126185A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL12618597A 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor, a water soluble vitamin e compound and a hydrophilic non-aqueous solvent IL126185A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations
PCT/EP1997/001438 WO1997035587A1 (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs

Publications (2)

Publication Number Publication Date
IL126185A0 IL126185A0 (en) 1999-05-09
IL126185A true IL126185A (en) 2003-05-29

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12618597A IL126185A (en) 1996-03-22 1997-03-21 Compositions comprising an hiv protease inhibitor, a water soluble vitamin e compound and a hydrophilic non-aqueous solvent

Country Status (12)

Country Link
JP (1) JP3117726B2 (ja)
AR (1) AR006345A1 (ja)
BG (1) BG64457B1 (ja)
CO (1) CO4790151A1 (ja)
HU (1) HU228026B1 (ja)
ID (1) ID16781A (ja)
IL (1) IL126185A (ja)
MY (1) MY126358A (ja)
OA (1) OA10880A (ja)
PL (1) PL187919B1 (ja)
TW (1) TW455491B (ja)
WO (1) WO1997035587A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1017366A4 (en) * 1996-09-01 2006-03-22 Pharmos Corp SOLID COPARCIPITATES FOR IMPROVED BIOVERABILITY OF LIPOPHILIC SUBSTANCES
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (es) * 1997-12-04 2000-10-16 Univ Granada Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
CA2432527A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
WO2004069180A2 (en) 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
ATE533473T1 (de) * 2004-09-24 2011-12-15 Boehringer Ingelheim Pharma Neue klasse von surfuctantähnlichen materialien mit vitamin-e-tpgs und wasserlöslichem polymer
WO2006039268A2 (en) * 2004-09-30 2006-04-13 Eastman Chemical Company Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016501A1 (en) * 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
CA2195027C (en) * 1991-11-08 2000-01-11 Joseph P. Vacca Hiv protease inhibitors useful for the treatment of aids
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ATE417836T1 (de) * 1992-12-29 2009-01-15 Abbott Lab Verfahren und intermediate zur herstellung von retroviralen proteasehemmern
DE69418035T2 (de) * 1993-01-15 1999-08-12 Agouron Pharma Hiv-proteaseinhibitoren
AU1046895A (en) * 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
HUT74681A (en) * 1993-12-15 1997-01-28 Merck & Co Inc N-(2-hydroxy-1-indenyl)-2-phenylmethyl-4-hydroxy-5-(2-carboxamido-piperazinyl)-pentaneamide derivatives of hiv protease inhibitor activity and phrmaceutical compositions contining them
AU699483B2 (en) * 1994-03-07 1998-12-03 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0825849A1 (en) * 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
TW455491B (en) 2001-09-21
ID16781A (id) 1997-11-13
BG102838A (en) 1999-09-30
BG64457B1 (bg) 2005-03-31
MY126358A (en) 2006-09-29
AR006345A1 (es) 1999-08-25
PL187919B1 (pl) 2004-11-30
JP3117726B2 (ja) 2000-12-18
HUP9901887A2 (hu) 1999-12-28
CO4790151A1 (es) 1999-05-31
WO1997035587A1 (en) 1997-10-02
IL126185A0 (en) 1999-05-09
OA10880A (en) 2001-10-11
JP2000500504A (ja) 2000-01-18
PL328916A1 (en) 1999-03-01
HUP9901887A3 (en) 2000-02-28
HU228026B1 (en) 2012-08-28

Similar Documents

Publication Publication Date Title
EP1074243A3 (en) Cosmetic compositions
AU3985897A (en) 1,3-diheterocyclic metalloprotease inhibitors
AU8875798A (en) Meta-benzamidine derivatives as serin protease inhibitors
HK1014950A1 (en) Hiv protease inhibitors.
IL126185A (en) Compositions comprising an hiv protease inhibitor, a water soluble vitamin e compound and a hydrophilic non-aqueous solvent
HUP0201591A3 (en) Pharmaceutical formulations comprising an hiv protease inhibitor
AU3118200A (en) Hiv integrase inhibitors
AU4723799A (en) Protease inhibitors
AU7666898A (en) Surfactant compositions
AU7139598A (en) Protease inhibitors
AU4092799A (en) Protease inhibitors
EP0797242A3 (en) Etching high aspect contact holes in solid state devices
EP0691345A3 (en) Combinations of HIV protease inhibitors
AUPM982594A0 (en) HIV protease inhibitors
AU9110298A (en) Protease inhibitors
AU9098598A (en) Aqueous preservative agents
AU2196400A (en) Cyanoacrylate compositions comprising a soluble antimicrobial agent
AU7133898A (en) Nanosized aspartyl protease inhibitors
AU9300298A (en) Protease inhibitors
AU2713100A (en) Protease inhibitors
AU6828894A (en) Hiv protease inhibitors
AU6900001A (en) Improving the performance of a cdma system
AU3146997A (en) Pediatric formulation for hiv protease inhibitors
AP9801343A0 (en) Compositions comprising an hiv protease inhibitor such as vx478 and a water soluble vitamin e compound such as vitamin e-pgs
AU7689798A (en) Vif-derived hiv protease inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired